IIL's Combo Vaccine Wins Big Indian Tender, But Pentavalent Concerns Linger
State-owned Indian Immunologicals Ltd., one of the local companies aiming to challenge the dominance of multinationals in the domestic Indian vaccine market, has come up with a low-priced five-in-one jab for children that the government is including in its massive national immunization program.
You may also be interested in...
The entry of India’s state-owned Indian Immunologicals and partner Griffith University in the COVID-19 vaccine race could potentially disrupt pricing dynamics. The alliance is developing a live-attenuated, single dose vaccine, which it hopes will be ready for launch in 18-24 months.
Panacea Biotec has allied with the world’s largest-vaccine maker, the Serum Institute of India, to ramp up production of a six-in-one jab aimed at preventing killer diseases like polio and diphtheria and target a global market estimated to be worth over $1.25bn annually.
India's health minister has announced an ambitious target of ensuring a full child immunization rate of 95% in the next 18 months, up from an overall rate of 65% now, and has appealed to the private sector to help achieve the goal.